Table 2.
Functional status and characteristics of the disease according to socioeconomic status
| Variable | Totalb | SES 1–2 | SES 3–6 | p** |
|---|---|---|---|---|
| Karnofskyd,a | 90 (30–100) | 90 (30–100) | 90 (40–100) | 0.056 |
| Comorbiditiesc, n (%) | ||||
| High blood pressure | 802 (17.3) | 554 (16.1) | 248 (21.2) | < 0.0001 |
| Type 2 Diabetes Mellitus | 607 (13.1) | 455 (13.2) | 152 (13) | 0.837 |
| Other | 438 (9.4) | 279 (8.1) | 148 (12.6) | < 0.0001 |
| Onset of symptomsc, n (%) | ||||
| > 6 months | 1750 (38.7) | 1357 (40.9) | 386 (35.1) | 0.003 |
| 3–6 months | 1186 (26.2) | 868 (26.2) | 314 (28.5) | |
| < 3 months | 1497 (33.1) | 1093 (32.9) | 400 (36.4) | |
| No data | 93 (2.1) | |||
| Characteristics of the disease | ||||
| Histologyc, n (%) | ||||
| Squamous-cell carcinoma | 3782 (81.7) | 2844 (82.9) | 924 (79.4) | 0.02 |
| Adenocarcinoma | 537 (11.6) | 376 (11) | 160 (13.7) | |
| Other | 292 (6.3) | 210 (6.1) | 80 (6.9) | |
| No data | 20 (0.4) | |||
| Clinical stagec, n (%) | ||||
| Early (IA1-IB1) | 685 (14.8) | 485 (14.1) | 200 (17.1) | 0.023 |
| Locally advanced (IB2-IVA) | 3399 (73.4) | 2539 (73.7) | 848 (72.4) | |
| Advanced (IVB), relapsed or persistent | 547 (11.8) | 419 (12.2) | 123 (10.5) | |
| Characteristics of cancer treatment | ||||
| Early stagesc, n (%) | ||||
| Surgery | 368 (53.7) | 259 (53.4) | 109 (54.5) | 0.442 |
| Surgery + adyuvance | 163 (23.8) | 112 (23.1) | 51 (25.5) | |
| Other | 94 (13.7) | 73 (15.1) | 21 (10.5) | |
| None | 60 (8.8) | 41 (8.5) | 19 (9.5) | |
| Locally advanced stagesc, n (%) | ||||
| CRT + BT | 1959 (57.6) | 1469 (57.9) | 489 (57.7) | 0.404 |
| Palliative care | 11 (0.3) | 10 (0.4) | 1 (0.1) | |
| Other | 870 (25.6) | 656 (25.8) | 209 (24.6) | |
| None | 559 (16.4) | 404 (15.9) | 149 (17.6) | |
| Advanced, relapsed or persistentc, n (%) | ||||
| CT | 129 (23.5) | 100 (23.9) | 28 (22.8) | 0.818 |
| Palliative care | 29 (5.3) | 21 (5) | 8 (6.5) | |
| Other | 266 (48.6) | 207 (49.4) | 57 (46.3) | |
| None | 123 (22.5) | 91 (21.7) | 30 (24.4) | |
SES socioeconomic status
**p value represents differences between SES 1–2 vs. SES 3–6. p < 0.05 is indicated in Bold font. CRT + BT Concomitant chemoradiation therapy followed by brachytherapy, CT chemotherapy
aMedian (minimum–maximum)
bNo record of SES was found for 17 patients
cChi-squared test
dMann–Whitney U test